1. Introduction
===============

Gastric inflammation, ulcer, and cancer are induced by *H. pylori* infection. *H. pylori* is also responsible for other disorders like skin, oropharynx, endocrine, respiratory, haemopoietic, central nervous system, eye and reproductive system, *etc*. \[[@r1], [@r2]\]. Bacterial virulence factors are important for the development of gastric carcinoma \[[@r3], [@r4]\]. Stomach cancer is increased by the presence of the Cag Pathogenicity Island (PAI) of which a Cag gene encodes an immunodominant protein called CagA. This belongs to the type IV secretion system along with it VirB proteins. Zanotti and Cendron \[[@r5]\] revealed a large number of copies of CagA and VirB proteins in the type IV secretion system. Once CagA is injected into the host cell, tyrosine is phosphorylated, which interferes with several cancer pathways \[[@r5]\]. Reproduction in male and females is also affected by *H. pylori* infection \[[@r6]-[@r8]\]. These bacterial genes/virulence factors of the pathogenic islands represent a promising source for identifying novel drug targets.

Identification and validation of novel drug targets is a key process for discovery of new compounds. Various methods and approaches are available for discovery and validation of drug targets for infectious diseases \[[@r9]\]. Dutta *et al.* \[[@r10]\] used subtractive genomics for identification of essential genes in *H. pylori* strain HpAG1, Hp26695 and J99. Kiranmayi *et al.* \[[@r11]\] identified essential transporter genes in *H. pylori* using bioinformatics approaches. Neelapu and Pavani \[[@r12]\] identified 17 novel drug targets in *H. pylori* strains HpB38, HpP12, HpG27, HpShi470, HpSJM180 using *in-silico* genome and proteome analysis, whereas in a similar type of analysis carried out in the strain HpAG1 29 novel drug targets were identified \[[@r13]\]. Nammi *et al.* \[[@r14]\] used comparative genomics, proteomics *etc*. for 23 *H. pylori* strains to identify 29 novel drug targets. Mandal and Das \[[@r15]\] used *in-silico* approach for identifying drug targets in *H. pylori.* Sarkar *et al.* \[[@r16]\] used metabolic pathway analysis to identify drug targets in *H. pylori*. Cai *et al.* \[[@r17]\] used reverse docking to identify drug targets in *H. pylori*. However, there are no specific reports to date, on screening of pathogenic islands in *H. pylori* to identify drug targets. Therefore, the current paper deals with screening of pathogenic islands to identify novel drug targets in 23 strains of *H. pylori*.

2. Materials and Methods
========================

2.1. Sampling
-------------

Genomes of 23 *H. pylori* strains *Hp*F32 \[[@r18]\], *Hp*F30 \[[@r18]\], *Hp*2017 \[[@r19]\], *Hp*2018 \[[@r19]\], *Hp*26695 \[[@r20]\], *Hp*35A \[[@r21]\], *Hp*51 \[[@r22]\], *Hp*52 \[[@r23]\], *Hp*CuZ20 \[[@r24]\], *Hp*F16 \[[@r18]\], *Hp*F57 \[[@r18]\], *Hp*INDIA7 \[[@r25]\], *Hp*SAT464 \[[@r26]\], *Hp*J99 \[[@r27]\], *Hp*B8 \[[@r28]\], *Hp*908 \[[@r29]\], *Hp*83 \[[@r30]\], *Hp*SJM180 \[[@r31]\], *Hp*AG1 \[[@r32]\], *Hp*Shi470 \[[@r33]\], *Hp*G27 \[[@r34]\], *Hp*P12 \[[@r35]\] and *Hp*B38 \[[@r36]\] are sampled based on availability of complete genome, strain history, pathogenicity report of the strains and geographical origin. In our study, identification of novel drug targets for *H. pylori* has been accomplished for the first time for all the 23 *H. pylori* strains by using an integrated approach of genome, proteome and primary property analysis followed by protein-protein interactions of genes/proteins and host-pathogen interactions using computational resources.

2.2. Screening of Pathogenic Islands by *In silico* Genome Analysis for Drug Targets
------------------------------------------------------------------------------------

Islands viewer \[[@r37]\] is used to identify pathogenic islands and the virulence genes in pathogenic islands for 23 *H. pylori* strains. Islands viewer is an integrated tool with different genomic island prediction methods such as Island Pick, SIGI-HMM and Island Path. These methods identify virulence genes in genomic islands based on three different criteria and methods. Island Pick is used to identify genomic islands and non-genomic islands. SIGI-HMM identifies genomic islands based on sequence composition, GC% and codon usage by implementing Hidden Markov model. Island Path (DIMOB) identifies functionally related mobile genes like transposases, integrases and abnormal sequence composition based on the origin of the genome. Complete genomes of 23 *H. pylori* strains were submitted to the Islands viewer to screen and identify pathogenic islands in the respective genomes and the virulence genes in pathogenic islands. These virulence genes were screened and confirmed for non homology as per the procedure of Neelapu *et al.* \[[@r13]\]. Potential drug targets among the pool of catalogued virulence genes were identified as per the procedure of Neelapu *et al.* \[[@r13]\].

2.3. Prediction of Protein-protein Interactions
-----------------------------------------------

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) at <http://string-db.org/> is used to predict the protein interactions for the 31 drug targets \[[@r38]\]. STRING is a database consisting of the known and predicted protein interactions data for more than 2000 organisms. Protein-protein interactions were performed based on amino acid sequence for each drug targets. Amino acid sequence of each drug target was submitted to the STRING database against organism *H. pylori*.

2.4. Network Analysis
---------------------

Cytoscape v3.3.0 is a popular bioinformatics tool for biological network visualization and data integration \[[@r39]\]. Cytoscape was used to integrate and visualize the biological network data predicted in STRING. STRING network data consisting of 609 predicted partners for 31 drug targets is imported to Cytoscape. The network data was integrated using option union to predict and visualize the comprehensive network of 609 predicted partners. Network analysis of Network Analyzer of Cytoscape v3.3.0, was used to compute closeness centrality, stress centrality, betweenness centrality, distribution, shortest path length distribution, shared neighbors distribution, node degree distribution, neighbourhood connectivity distribution, node degree distribution, *etc*., along with other simple parameters of the network such as number of nodes, connected components, network diameter, network radius, network centralization, clustering coefficient, number of selfloops, multi-edge node pairs, shortest paths, characteristic path length, average number of neighbors, network density, network heterogeneity. Data integrated in network was visualized using organic of Y files layout.

2.5. Prediction of Host-Pathogen Interactions
---------------------------------------------

Host-pathogen interactions help us to understand the role and mechanism of infection paving path to understand and identify more efficient strategies to cure or prevent infection. Host-pathogen interaction studies were performed in two ways -- first option is by using host-pathogen interaction tools and second option is by text mining of the literature. The following tools were employed to predict the host pathogen interactions: Pathogen-Host interaction search tool (PHISTO) \[[@r40]\], Pathosystems Resource integration Center (PATRIC) \[[@r41]\] and Host Pathogen Interaction Database (HPIDB) \[[@r42]\]. In addition, text mining of literature was performed using drug targets and its predicted interacting partners for data host pathogen interactions.

3. Results
==========

3.1. Potential Drug Targets for *H. pylori*
-------------------------------------------

Island Pick, SIGI-HMM and Island Path methods of Islands viewer predicted 31 pathogenic islands with genes/virulence factors for 22 *H. pylori* strains (Table **[1](#T1){ref-type="table"}**). No pathogenic islands were detected in *H. pylori* strain HpSAT464. The features of the pathogenic islands predicted are mentioned in Table **[2](#T2){ref-type="table"}**. Nearly 642 genes/virulence factors associated with pathogenic islands were identified in 23 *H. pylori* strains Table **[2](#T2){ref-type="table"}**. Of them 282 were known with known functions and rest 361 were hypothetical proteins (Table **[2](#T2){ref-type="table"}**). Analysis of 642 bacterial genes identified 101 genes which are non-homologous to humans and are essential for pathogen. Gene property analysis of 101 genes identified 31 potential drug targets (Table **[3](#T3){ref-type="table"}**).

Literature screening based on the keywords identified that all the drug targets are experimentally validated. Sixteen of the 31 predicted drug targets are critical for the survival of *H. pylori*. Analysis showed that GTPase, transposase, conjugal transfer protein, cag island DNA transfer protein cag 5, cag pathogenicity island protein Cag 3, cag pathogenicity island protein CagC, type IV secretion system protein virB8, type IV secretion system protein VirB4, type IV secretion system protein VirB9, cag pathogenicity island protein M, cag pathogenicity island protein W/9, relaxase, competence protein comB9-like competence protein, ATPase, Holliday junction resolvase, type II adenine specific DNA methyltransferase might be the critical drug targets for survival of *Helicobacter* species.

3.2. Protein-protein Interactions
---------------------------------

STRING's reliable algorithms predicted protein-protein interactions for *H. pylori* in three modes-confidence view, evidence view and action view. Twenty six of the 31 drug targets demonstrated interactions with other proteins, whereas no partners were predicted for rest five of the drug targets (Supplementary Table **1**). The evidence view presents information from different sources such as neighbourhood, coexpression, text mining, homology and gene fusion. The evidence view for the 23 drug targets is presented in Fig. (**[1](#F1){ref-type="fig"}**). Action view presents interacting information regarding activation, inhibition, binding, phenotype, catalysis, post translation modification and expression whereas confidence view presents score between interaction partners. STRING predicted 609 interacting partners for the 23 drug targets in three modes (Fig. **[1](#F1){ref-type="fig"}**; Supplementary Table **1**).

3.3. Network Analysis
---------------------

Network analysis on twenty three networks were predicted in STRING when exported and merged in cytoscape. Data visualization and analysis on the merged network demonstrated different protein hubs in the merged network (Figs. **[2](#F2){ref-type="fig"}**-**[6](#F6){ref-type="fig"}**). Protein-protein interactions in bird eye view with 361 nodes and 3146 edges of 609 interacting partners were revealed by cytoscape (Fig. **[2A](#F2){ref-type="fig"}**). Very important interactions with specific proteins responsible for gastric cancer were visualized in protein hubs. Protein-protein interactions of drug target C694_01330 (Type II adenine specific DNA methyl tranferase can be visualized in Fig. (**[2B](#F2){ref-type="fig"}**) by cytoscape. Protein-protein interactions of hub (pz33sb) with IS606A transposase and IS605A transposase were as visualized in Fig. (**[3](#F3){ref-type="fig"}**). Protein-protein interactions of drug target ruvC (Holiday junction resolvase) with DNA repair system is visualized in Fig. (**[4](#F4){ref-type="fig"}**). Blocking the drug target/hub of the pathogen with a molecule would lack DNA repairing mechanism affecting survival of the organism.

Protein-protein interactions of drug targets Cag 5, Vir B, Vir B8, pz19b (mechanosenstive ion channel protein), ftsz/obg/GTPase, Com9 (DNA transformation competence protein), pz23sb (PARA protein), Vir B4 with Che V (chemotaxis proteins), adhesion proteins like BabA, and toxins like Vac A are visualized in Fig. (**[5](#F5){ref-type="fig"}**). Interfering with these drug targets which are related to organism movement, adhesion of the organism with the host, and transfer of toxins to host would result in retardation of the growth. Protein-protein interactions of drug targets Cag E, Vir B11, ISO606B transposase with Ure A (urease sububnit aplha) are visualized in Fig. **[6](#F6){ref-type="fig"}**. Urease is an important enzyme for neutralizing the acid in the host and lacking this enzyme would be fatal for pathogen.

3.4. Host-pathogen Interactions
-------------------------------

Tools PHISTO, PATRIC and HPIDB predicted host pathogen interactions. PHISTO predicted five interactions between host and pathogen proteins Table **[4](#T4){ref-type="table"}**; (Fig. **[7A](#F7){ref-type="fig"}**). Tyrosinase-protein phosphatase non-receptor type II, NCK-interacting protein with SH3 domain, serine/threonine protein kinase MARK2, mitogen-activated protein kinase kinase kinase 7 (MAPKKK7) and TNF receptor associated factor 6 are the proteins from host involved in interactions Table **[4](#T4){ref-type="table"}**; (Fig. **[7A](#F7){ref-type="fig"}**). Cytotoxin associated immunodominant antigen (with protein ID\'s P80200, P55980, B5Z6S0, Q9ZLT1) and vacuolating cytotoxin A (Q8RNUI) are the proteins from pathogen involved in interactions Table **[4](#T4){ref-type="table"}**; (Fig. **[7A](#F7){ref-type="fig"}**). Tyrosinase-protein phosphatase non-receptor type II (Q06124), serine/threonine protein kinase MARK2 (Q9NZQ3), mitogen-activated protein kinase kinase kinase 7 (MAPKKK7) (O43318), TNF receptor associated factor 6 (Q9Y4K3) of host interacted with cytotoxin associated immunodominant antigen with protein ID\'s P80200, P55980, B5Z6S0, Q9ZLT1 of pathogen respectively Table **[4](#T4){ref-type="table"}**; (Fig. **[7A](#F7){ref-type="fig"}**). PHISTO also predicted NCK-interacting protein with SH3 domain (Q9NZQ3) of host interacting with vacuolating cytotoxin A (Q8RNUI) of pathogen Table **[4](#T4){ref-type="table"}**; (Fig. **[7A](#F7){ref-type="fig"}**).

HPIDB visualized interactions between 54 proteins from different pathogens with three human proteins (Table **[4](#T4){ref-type="table"}**; Fig. **[7B](#F7){ref-type="fig"}**). Proteins 22, 1, 20, 11 were predicted for bacteria, fungi, virus, animal respectively. Among these pool 22 bacterial proteins two proteins from *H. pylori* were interacting with three human proteins (Table **[4](#T4){ref-type="table"}**). HPIDB predicted three interactions between host and pathogen (Table **[4](#T4){ref-type="table"}**; Fig. **[7B](#F7){ref-type="fig"}**). Tyrosinase-protein phosphatase non-receptor type II (Q06124), mitogen-activated protein kinase kinase kinase 7 (MAPKKK7) (O43318) and NCK-interacting protein with SH3 domain (Q9NZQ3) are the proteins from host involved in interactions with cytotoxin associated immunodominant antigen A (with protein ID\'s P80200; B5Z6S0) of pathogen Table **[4](#T4){ref-type="table"}**; (Fig. **[7B](#F7){ref-type="fig"}**).

PATRIC predicted five interactions between host and pathogen Table **[4](#T4){ref-type="table"}**; (Fig. **[7C](#F7){ref-type="fig"}**, **[D](#F7){ref-type="fig"}**). Tyrosinase-protein phosphatase non-receptor type II, mitogen-activated protein kinase kinase kinase 7 (MAPKKK7), serine/threonine protein kinase MARK2 and TNF receptor associated factor 6 are the proteins from host involved in interactions Table **[4](#T4){ref-type="table"}**; (Fig. **[7C](#F7){ref-type="fig"}**, **[D](#F7){ref-type="fig"}**). Cytotoxin associated immunodominant antigen (with protein ID B5Z6S0) and Cytotoxin associated immunodominant antigen A (with protein ID P80200) are the proteins from pathogen involved in interactions Table **[4](#T4){ref-type="table"}**; (Fig. **[7C](#F7){ref-type="fig"}**, **[D](#F7){ref-type="fig"}**). Serine/threonine protein kinase MARK2 (Q9NZQ3), mitogen-activated protein kinase kinase kinase 7 (MAPKKK7) (O43318), TNF receptor associated factor 6 (Q9Y4K3) and NCK-interacting protein with SH3 domain (Q9NZQ3) of host interacted with cytotoxin associated immunodominant antigen A (P80200) of pathogen respectively Table **[4](#T4){ref-type="table"}**; (Fig. **[7C](#F7){ref-type="fig"}**, **[D](#F7){ref-type="fig"}**). PATRIC also predicted tyrosinase-protein phosphatase non-receptor type II (Q06124) of host interacting with cytotoxin associated immunodominant antigen (B5Z6S0) of pathogen respectively Table **[4](#T4){ref-type="table"}**; (Fig. **[7C](#F7){ref-type="fig"}**, **[D](#F7){ref-type="fig"}**). In addition text mining of literature showed that eight proteins of *H. pylori* are interacting with 14 human proteins Table **[5](#T5){ref-type="table"}**.

4. Discussion
=============

Discovery, identification and validation of drug targets have been a debate from long time. Recent advances on discovery and validation of drug targets for infectious diseases focused on disease understanding and mechanism. Previously subtractive genomics \[[@r11]-[@r13]\] was implemented by our group to identify novel drug targets for 23 *H. pylori* strains. Different methods like essential gene identification \[[@r10], [@r11]\], metabolic pathway analysis \[[@r16]\] and reverse docking \[[@r17]\] were implemented by other groups to identify novel drug targets for *H. pylori.* Though, these methods were successful in identifying novel drug targets for *H. pylori* we foresee pathogenic islands as the potential source for novel drug targets.

The current study was the first report till date to employ successful systematic *insilico* analysis for identification of potential and novel drug target candidates from pathogenic islands of 23 *H. pylori* strains. Systematic *in silico* analysis included five steps - the first two steps were used to identify drug targets and the next three steps were used to characterize the drug targets. The initial step in the systematic analysis is to screen the genome of *H. pylori* strains to identify pathogenic islands. Screening the genome of *H. pylori* strains using islands viewer \[[@r37]\] identified 31 pathogenic islands Table **[1](#T1){ref-type="table"}**. The second step is to analyzae the pathogenic islands to identify the potential drug targets for

*H. pylori.* Analysis of the pathogenic islands resulted in identification of 642 virulence factors (bacterial genes) in 31 pathogenic islands Table **[2](#T2){ref-type="table"}**. The analysis of the 642 virulence factors identified 101 genes which were non-homologous to human and are essential for the survival of the pathogen. Further, analysis of 101 genes for gene property identified 31 novel and potential drug targets for *H. pylori* Table **[3](#T3){ref-type="table"}**. The third step in the systematic analysis is to implement protein-protein interactions to identify the interacting partners for the potential drug targets. STRING was used to study the protein-protein interactions and predicted 609 interacting partners for the 23 drug targets (Fig. **[1](#F1){ref-type="fig"}**); Supplementary Table **1**. The fourth step is to accomplish network analysis on the interacting partners associated in the protein-protein interactions. Data of twenty three networks was exported and merged in cytoscape to perform network analysis. Data visualization and analysis on the merged network demonstrated bird eye view of different protein hubs in the merged network with 361 nodes and 3146 edges of 609 interacting partners (Fig. **[2A](#F2){ref-type="fig"}**). And the fifth and final step in the systematic analysis is to proceed with the host-pathogen interactions based on tools and literature mining. PHISTO, PATRIC and Host Pathogen Interaction Database were used to predict the host pathogen interactions for predicted interacting partners. Host-pathogen interactions identified important molecules which are closely associated with gastric cancer. These studies persuaded us to ascertain key molecules in *H. pylori* and their counter interacting molecules in the host leading to gastric cancer.

Data on protein-protein interactions, network analysis and host-pathogenic interactions provided few insights and understanding of *H. pylori* associated gastric cancer. As revealed by the data in the present study *H. pylori* uses cytokines, gastrin and toxin VacA to weaken the gastric mucosal barrier and colonize in the submucous. After the gastric mucosal barrier is weakened BabA facilitates *H. pylori* in adhering to the epithelial lining of the stomach \[[@r58]-[@r62]\]. T4SS system coded by cytotoxin associated gene pathogenicity island (cag PAI) injects CagA, peptidoglycan and VacA into the host to establish interaction with the host leading to inflammation, a condition known as gastritis.

Cag A changes the expression of host cells; induces elongation of cell, loss of cell polarity and cell proliferation; decreases acid secretion; and degrade cell-cell junctions \[[@r63]\]. CagA is phosphorylated and activated by src/Lyn kinase disturbing mitogen-activated protein kinase (MAPK) signaling in host cells through NCK-interacting with SH3/SH2 domain to modify cellular responses \[[@r64]\]. Cell focal adhesions are disrupted by CagA by binding and activating SHP2 phosphates/Tyrosine protein phosphatase non receptor type 11 \[[@r64]\]. Normal epithelial architecture is disrupted when polarity regulator PAR1b/MARK2 kinase is inhibited by CagA leading to loss of polarity in epithelial cells \[[@r64]\]. Another surface receptor protein in *H. pylori* Toll like receptor (TLR)-2 disrupts adherin junctions within gastricepithelial cells. TLR-2 activates protease calpain cleaving E-cadherin and allows increased β-catenin signaling to disrupt adherin junctions \[[@r65]\]. CagA-dependent, TRAF6-mediated Lys 63-ubiquitination and activation of TAK1 activate transcription factor NF-κβ, resulting in chronic inflammation and cancer when is constitutively expressed \[[@r66]-[@r68]\]. CagA and COX-2 were known for cell proliferation, prostaglandin biosynthesis and angiogenesis. Cag A induces proteasome mediated degradation directly by inactivating gastric tumor suppressor gene RUNX3 \[[@r69], [@r70]\] or indirectly p53 to modulate ASPP2 tumor suppressor genes \[[@r71]\].

Vacuolating cytotoxin (Vac) A induce ROS at the site of infection damaging mitochondrial DNA of gastric epithelial cells \[[@r44]\]. Vac A interact with a number of host surface receptors to trigger responses such as poreformation, cell vacuolation, endolysomal functions modification, immune inhibition and apoptosis \[[@r72]-[@r74]\]. VacA along with other virulence factors such as γ-glutamyl transpeptidase, and cholesterol α-glucosides modulate responses of T cells. Cag A and Vac A induce ROS and NF-κβ, along with cytokines, and chemokines.

Cytokines (IL-1, 6, 8), chemokines (CXCL8, CCL3, 4), metalloproteinases (MMPs), prostaglandin E2 (PGE2) and reactive oxygen nitrogen species (RONS) prolong inflammation inducing G cells to secrete the hormone gastrin in turn stimulating loads of acid damaging duodenum a condition known as ulcers \[[@r75], [@r76]\]. NF-κβ and β-catenin signaling pathways induce double stranded breaks, defective mitotic checkpoints, deregulate HR pathway of DSB repair and DNA repair enzymes leading to genetic diversification randomly heading towards activation of oncogenes and inactivation of tumor suppressor genes leading to gastric cancer \[[@r77]\].

CONCLUSION
==========

Pathogenic islands are the good source for drug targets. Analysis of genomes in 23 *H. pylori* strains identified 31 pathogenic islands of them 29 bacterial genes which are nonhomologous to humans and are essential for pathogen. All the drug targets were found to be critical for the species and are already experimentally validated lending credence to our approach. PHISTO, HPIDB, PATRIC tools visualized host-pathogen interactions directly or indirectly predicting the role of certain pathogen molecules (drug targets) in gastric cancer. These novel drug targets may have possible therapeutic implications for gastric cancer.
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![Evidence view of protein-protein interactions as predicted in STRING for 23 drug targets identified in *H. pylori* **A**). GTPase protein, **B**). ATPase protein, **C**). conjugal transfer protein **D**). Cag 5 protein **E**). Cag C protein, **F**). Cag 3 protein, **G**). integrase/recombinase (XERCD family) protein, **H**).Vir B4 protein, **I**). Vir B9 protein, **J**). Periplasmic competence protein, **K**). Poly E rich protein, **L**). Cag 9 protein, **M**). PARA protein, **N**). Relaxase protein, **O**). Competence like protein, **P**). Com B9 like protein, **Q**). Holiday junction resolvase protein, **R**). Type II adenine methyl transferase protein, **S**). Outer membrane HorC protein, **T**). Cag M protein, **U**). Mechanosensitive channel protein, **V**). Transposase protein, **W**). Type IV secretion system VirB8 protein.](CG-18-450_F1){#F1}

![**A**) Bird eye view of protein-protein interactions with 361 nodes and 3146 edges of 609 interacting partners as revealed by cytoscape. **B**) Protein-protein interactions of drug target C694_01330 (Type II adenine specific DNA methyl tranferase) highlighted in rectangle box as revealed by cytoscape.](CG-18-450_F2){#F2}

![Protein-protein interactions from the hub pz33sb highlighted in rectangle box with IS606A transposase and IS605A transposase as revealed by cytoscape.](CG-18-450_F3){#F3}

![Protein-protein interactions of drug target ruvC (Holiday junction resolvase) highlighted in rectangle box with other DNA repair system as revealed by cytoscape.](CG-18-450_F4){#F4}

![Protein-protein interactions of drug targets Cag 5, Vir B, Vir B8, pz19b (mechanosenstive ion channel protein), ftsz/obg/GTPase, Com9 (DNA transformation competence protein), pz23sb (PARA protein), Vir B4, with Che V(chemotaxis proteins), adhesion proteins like BabA, and toxins like Vac A as revealed by cytoscape.](CG-18-450_F5){#F5}

![Protein-protein interactions of drug targets Cag E, Vir B11, ISO606B transposase with Ure A (urease sububnit aplha) as revealed by cytoscape.](CG-18-450_F6){#F6}

![Host and pathogen interactions as visualized by **A**) PHISTO **B**) HPIDB **C&D**) PATRIC.](CG-18-450_F7){#F7}

###### 

Pathogenic islands identified in 23 *H. pylori* strains.

  **S. No**   **Strain Name**   **No of Genomic Islands**   **Method**         **Start Position**   **End Position**   **Size**
  ----------- ----------------- --------------------------- ------------------ -------------------- ------------------ ----------
  1           Hp57              1                           IslandPath-DIMOB   284,185              324,544            40,359
  2           Hp12              1                           IslandPath-DIMOB   484,957              489,788            4,831
  3           HpB8              1                           IslandPath-DIMOB   448,052              533,220            85,168
  4           Hp India 7        3                           IslandPath-DIMOB   749,965              797,920            47,955
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   1,217,751            1,246,359          28,608
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   1,616,790            1,626,196          9,406
  5           Hp51              1                           IslandPath-DIMOB   992,739              1,036,302          43,563
  6           HpF32             1                           IslandPath-DIMOB   1,051,313            1,085,082          33,769
  7           HpF16             2                           IslandPath-DIMOB   470,749              493,591            22,842
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   832,543              872,347            39,804
  8           HpF30             1                           IslandPath-DIMOB   828,728              868,864            40,136
  9           Hp35A             1                           IslandPath-DIMOB   1,032,831            1,072,644          39,813
  10          HpB38             1                           IslandPath-DIMOB   1,509,346            1,522,857          13,511
  11          Hp2018            1                           IslandPath-DIMOB   982,216              1,004,243          22,027
  12          Hp908             1                           IslandPath-DIMOB   973,392              990,660            17,268
  13          Hp2017            2                           IslandPath-DIMOB   497,212              532,400            35,188
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   974,279              996,463            22,184
  14          HpAG1             1                           IslandPath-DIMOB   512,700              550,135            37,435
  15          HpSJM180          1                           IslandPath-DIMOB   1,372,341            1,416,207          43,866
  16          HpJ99             2                           IslandPath-DIMOB   908,817              912,007            3,190
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   1,010,607            1,061,274          50,667
  17          HpShi470          1                           IslandPath-DIMOB   874,701              915,726            41,025
  18          HpG27             1                           IslandPath-DIMOB   1,045,375            1,082,440          37,065
  19          HpCuz20           3                           IslandPick         205,446              215,461            10,015
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   226,353              260,258            33,905
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   562,530              600,842            38,312
  20          Hp26695           2                           IslandPath-DIMOB   449,710              479,634            29,924
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   1,042,255            1,070,401          28,146
  21          Hp83              2                           IslandPath-DIMOB   73,583               107,449            33,866
  \_\_        \_\_              \_\_                        IslandPath-DIMOB   852,516              892,293            39,777
  22          Hp52              1                           IslandPick         654,123              662,394            8,271

###### 

Proteins and drug targets identified in pathogenic islands for 23 *H. pylori* strains.

  **S. No**   **Strain Name**   **No. of Pathogenic Islands**   **No. of Proteins**   **No. of Hypothetical Proteins**   **No. of Potential Drug Targets**   **No. of Drug Targets**
  ----------- ----------------- ------------------------------- --------------------- ---------------------------------- ----------------------------------- -------------------------
  1           Hp51              1                               9                     12                                 5                                   3
  2           HpF32             1                               12                    25                                 11                                  2
  3           HpF16             2                               11                    15                                 10                                  2
  4           HpF30             1                               28                    2                                  7                                   1
  5           Hp35A             1                               32                    4                                  9                                   3
  6           HpB38             1                               13                    4                                  3                                   2
  7           Hp2018            1                               11                    12                                 2                                   1
  8           Hp908             1                               6                     14                                 0                                   0
  9           Hp2017            2                               28                    5                                  3                                   2
  10          HpHPAG1           1                               31                    0                                  10                                  1
  11          HpSJM180          1                               9                     24                                 6                                   3
  12          HpJ99             2                               2                     4                                  0                                   0
  13          HpG27             1                               9                     16                                 6                                   5
  14          HpShi470          1                               8                     27                                 4                                   2
  15          HpcuZ20           3                               4                     7                                  0                                   1
  16          Hp83              2                               13                    34                                 8                                   2
  17          Hp26695           2                               9                     18                                 2                                   0
  18          HpIndia7          3                               10                    27                                 7                                   1
  19          HpB8              1                               21                    65                                 5                                   3
  20          Hp12              1                               2                     0                                  0                                   0
  21          HpF57             1                               11                    24                                 3                                   2
  22          Hp52              1                               4                     4                                  0                                   0
  23          HpSAT464          0                               0                     0                                  0                                   0
  Total                         31                              282                   361                                101                                 36

###### 

Drug targets identified in the 23 *H. pylori* strains.

  **S. No**             **Drug Target**                                  **Metabolic Categories**   **Gene ID**    **Strain Name**
  --------------------- ------------------------------------------------ -------------------------- -------------- -----------------
  **1**                 GTPase                                           Cellular process           GI:387782588   Hp51
  **2**                 DNA transfer protein                             Cellular process           GI:387782591   Hp51
  **3**                 Transposase                                      Cellular process           GI:385224738   Hp83
  **4**                 Putative IS606 transposase                       Cellular process           GI:385223561   Hp2017
  **5**                 Conjugal transfer protein                        Cellular process           GI:317181586   Hp57
  **6**                 Bacteriophage-related integrase                  Cellular process           GI:384892219   HpcuZ20
  **S. No**             **Drug Target**                                  **Metabolic Categories**   **Gene ID**    **Strain Name**
  **7**                 Cag island DNA transfer proteinCag C             Cellular process           GI:208434927   HpG27
  **8**                 Cag pathogenicity island protein 5               Cellular process           GI:384896154   Hp35A
  **9**                 Cag pathogenicity island protein 3               Cellular process           GI:385223565   Hp2017
  **10**                Integrase/recombinase XercD family protein       Cellular process           GI:308185118   HpSJM180
                                                                         Cellular process           GI:188527674   HpShi470
  **11**                Type IV secretion system protein virB8           Virulence factors          GI:298355174   HpB8
  **12**                Type IV secretion system protein VirB4           Virulence factors          GI:298355233   HpB8
  **13**                Type IV secretion system protein VirB9           Virulence factors          GI:317009420   HpIndia7
  **14**                Periplasmic competence protein-like protein      Virulence factors          GI:308185123   HpSJM180
  Virulence factors     GI:208434936                                     HpG27                                     
  **15**                Poly E-rich protein                              Information and storage    GI:385216250   HpF32
  **16**                Cag pathogenicity island protein M               Metabolism molecule        GI:384896163   Hp35A
  **17**                Cag pathogenicity island protein 9               Metabolism molecule        GI:108562930   HpHPAG1
  Metabolism molecule   GI:3848449915                                    HpF30                                     
  **18**                Cag pathogenicity island protein W               Metabolism molecule        GI:384896173   Hp35A
  **19**                Hac prophage II protein                          Metabolism molecule        GI:254780055   HpB38
  **20**                Hac prophage II integrase                        Metabolism molecule        GI:254780053   HpB38
  **21**                Mechanosensitive channel                         Metabolism molecule        GI:385231894   Hp2018
  **22**                Relaxase                                         Metabolism molecule        GI:308185146   HpSJM180
  **23**                Putative chromosome partitioning protein         Metabolism molecule        GI:298355190   HpB8
  **24**                VirB7                                            Metabolism molecule        GI:385224749   Hp83
  **25**                Competence protein                               Metabolism molecule        GI:208434918   HpG27
  **26**                ComB9-like competence protein                    Metabolism molecule        GI:208434919   HpG27
  **27**                ATPase                                           Metabolism molecule        GI:387782603   Hp51
  **28**                Outer membrane protein HorC                      Metabolism molecule        GI:385216248   HpF32
  **29**                PARA protein                                     Metabolism molecule        GI:208434932   HpG27
  Metabolism molecule   GI:188527681                                     HpShi470                                  
  Metabolism molecule   GI:317181592                                     Hp57                                      
  **30**                Holliday junction resolvase                      Metabolism molecule        GI:385217246   HpF16
  **31**                Type II adenine specific DNA methyltransferase   Metabolism molecule        GI:385217221   HpF16

###### 

Host -- pathogen interactions as predicted by tools PHISTO, PATRIC and HPIDB.

  **S. No**    **Host ID**   **Host**                                            **Pathogen ID**   **Pathogen**                                     **Interaction Type**   **Method**                         **Reference**
  ------------ ------------- --------------------------------------------------- ----------------- ------------------------------------------------ ---------------------- ---------------------------------- --------------------------------
  1            Q06124        Tyrosine-protein phosphatase non-receptor type 11   P80200            Cytotoxicity-associated immunodominant antigen   \-                     anti bait coimmunoprecipitation    Higashi *et al.* \[[@r43]\]
  2            Q9NZQ3        NCK-interacting protein with SH3 domain             Q8RNU1            Vacuolating cytotoxin A                          \-                     two hybrid/coimmunoprecipitation   de Bernard *et al.* \[[@r44]\]
  3            Q7KZI7        Serine/threonine-protein kinase MARK2               P55980            Cytotoxicity-associated immunodominant antigen   \-                     molecular sieving                  Nesić *et al.* \[[@r45]\]
  4            O43318        Mitogen-activated protein kinase kinase kinase 7    B5Z6S0            Cytotoxicity-associated immunodominant antigen   \-                     anti tag coimmunoprecipitation     Lamb *et al.* \[[@r46]\]
  5            Q9Y4K3        TNF receptor-associated factor 6                    Q9ZLT1            Cytotoxicity-associated immunodominant antigen   \-                     Other methods                      Zhu *et al.* \[[@r47]\]
  **PATRIC**                                                                                                                                                                                                  
  1            Q06124        Tyrosine-protein phosphatase non-receptor type 11   B5Z6S0            Cytotoxicity-associated immunodominant antigen   Physical association   Anti-tagcoimmuniprecption          Higashi *et al.* \[[@r43]\]
  2            O43318        Mitogen-activated protein kinase kinase kinase 7    P80200            Cytotoxin-associated protein A                   Physical association   Anti-tagcoimmuniprecption          Lamb *et al.* \[[@r46]\]
  3            Q06124        Tyrosine-protein phosphatase non-receptor type 11   P80200            Cytotoxin-associated protein A                   Physical association   Anti-tagcoimmuniprecption          Higashi *et al.* \[[@r43]\]
  4            Q7KZI7        Serine/threonine-protein kinase MARK2               P80200            Cytotoxin-associated protein A                   Direct interaction     Molecular seiving                  Nesić *et al.* \[[@r45]\]
  5            Q9Y4K3        TNF-receptor associated factor 6                    P80200            Cytotoxin-associated protein A                   Direct interaction     Anti-tagcoimmuniprecption          Lamb *et al.* \[[@r46]\]
  **HPIDB**                                                                                                                                                                                                   
  1            Q9NZQ3        NCK-interacting protein with SH3 domain             P80200            Cytotoxin-associated protein A                   Physical association   colocalization                     de Bernard *et al.* \[[@r44]\]
  2            Q06124        Tyrosine-protein phosphatase non-receptor type 11   B5Z6SO            Cytotoxin-associated protein A                   Physical association   anti bait coimmunoprecipitation    Higashi *et al.* \[[@r43]\]
  3            O43318        Mitogen-activated protein kinase kinase kinase 7    B5Z6SO            Cytotoxin-associated protein A                   Physical association   Anti-tagcoimmuniprecption          Lamb *et al.* \[[@r46]\]

###### 

Host -- pathogen interactions revealed from the text mining of the literature.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **S. No**                                                **Host Pathogen Interactions**             **Interactions Causes**         **Reference**                                 
  -------------------------------------------------------- ------------------------------------------ ------------------------------- --------------------------------------------- -----------------------------------
  1                                                        CagA                                       E-cadherin                      Gastric cancer                                Murata-Kamiya *et al.* \[[@r48]\]

  Erk mitogen-activated protein kinase                     Gastric cancer                             Zhu *et al.* \[[@r47]\]                                                       

  Transforming growth factor-b-activated kinase 1 (TAK1)   Gastric cancer                             Lamb *et al.* \[[@r46]\]                                                      

  Src family kinases                                       Gastric cancer                             Higashi *et al.* \[[@r49]\]                                                   

  human kinase PAR1b/MARK2                                 Gastric cancer                             Nesić *et al.* \[[@r45]\]                                                     

  2                                                        CagE type IV secretion system              Dendritic cells                 MALT and Gastric cancer                       Donald *et al.* \[[@r50]\]

  NF- B activator.\                                        Intestinal metaplasia and Gastric cancer   Hirata *et al.* \[[@r51]\]                                                    
  TAK1, TRAF6, and MyD88                                                                                                                                                            

  3                                                        Holliday junctions resolves                Mus81                           block DNA replication                         Chen *et al.* \[[@r52]\]

  4                                                        Mechanosensitive ion channel protein       integrin-b-catenin              human articular chondrocyte (HAC) responses   Lee *et al.* \[[@r53]\]

  Focal Adhesion Kinase pp125FAK                           osteoblast activation                      Rezzonico *et al.* \[[@r54]\]                                                 

  5                                                        Type IV secretion system                   protein kinase B, PKB           Gastric cancer                                King *et al.* \[[@r55]\]

  6                                                        GTPase                                     Guanine Nucleotide Exchange\    IL-8 expression                               Mossessova *et al.* \[[@r56]\]
                                                                                                      FactorSec7 Domain                                                             

  7                                                        Transpoase                                 RNA-proteins                    To regulate the RNA-proteins network          Kelley *et al.* \[[@r57]\]

  8                                                        VacA                                       VIP54                           Infection/Gastric cancer                      de Bernard *et al.* \[[@r44]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
